免疫检查点抑制剂治疗结直肠癌患者耐药的机理及其干预治疗  

Mechanism of immune checkpoint inhibitor resistance in colorectal cancer patients and its interventional strategies

作　　者：张美琪 金黑鹰[1] 王俊[1] 舒磊 Mei-Qi Zhang;Hei-Ying Jin;Jun Wang;Lei Shu(The Second Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210017,Jiangsu Province,China)

机构地区：[1]南京中医药大学第二附属医院,江苏省南京市210017

出　　处：《世界华人消化杂志》2024年第9期645-651,共7页World Chinese Journal of Digestology

基　　金：江苏省社会发展项目,No.BE2023786;江苏省研究生实践创新计划项目,No.SJCX24_1021.

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在黑色素瘤治疗中展现出的显著疗效,推动了其在多种实体瘤治疗中的广泛应用,目前已成为肿瘤治疗的主要手段之一,特别是在结直肠癌领域展现出巨大的潜力.然而在长期大样本的研究中发现其反应性偏低,存在原发性耐药与获得性耐药问题,严重影响治疗效果.本文拟对ICIs治疗结直肠癌患者耐药的机理及其干预治疗的研究进展作一综述,旨在为临床解决ICIs耐药问题提供新的思路.The remarkable efficacy demonstrated by immune checkpoint inhibitors(ICIs)in melanoma treatment has driven their widespread use in the treatment of a variety of solid tumours,and they have now become one of the mainstays of oncology treatment,especially in the field of colorectal cancer,where they have demonstrated great potential.However,in long-term large-sample studies,it was found that the response to ICIs is low,and there are problems of primary and acquired resistance,which seriously affect their therapeutic effect.In this paper,we will review the mechanism of resistance to ICIs in patients with colorectal cancer and the progress in research of interventional strategies for ICI resistance,aiming to provide new ideas for the solution of the problem of clinical drug resistance to ICIs.

关 键 词：免疫检查点抑制剂 免疫治疗 结直肠癌 耐药 

分 类 号：R735.3[医药卫生—肿瘤]